GeneDx Holdings Corp. (NASDAQ:WGS) Position Trimmed by Trexquant Investment LP

Trexquant Investment LP lowered its stake in GeneDx Holdings Corp. (NASDAQ:WGS) by 38.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 74,912 shares of the company’s stock after selling 47,100 shares during the quarter. Trexquant Investment LP’s holdings in GeneDx were worth $5,758,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also made changes to their positions in the company. MCF Advisors LLC grew its stake in GeneDx by 107.7% during the 4th quarter. MCF Advisors LLC now owns 351 shares of the company’s stock valued at $27,000 after acquiring an additional 182 shares in the last quarter. Global Retirement Partners LLC acquired a new position in shares of GeneDx during the 4th quarter valued at about $28,000. KLP Kapitalforvaltning AS acquired a new position in GeneDx during the fourth quarter valued at approximately $200,000. Evolution Wealth Advisors LLC bought a new position in GeneDx in the 4th quarter worth $202,000. Finally, Victory Capital Management Inc. bought a new position in shares of GeneDx in the fourth quarter worth about $209,000. 61.72% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. TD Cowen boosted their target price on shares of GeneDx from $75.00 to $118.00 and gave the stock a “buy” rating in a research report on Tuesday, January 7th. The Goldman Sachs Group increased their target price on GeneDx from $70.00 to $80.00 and gave the stock a “neutral” rating in a report on Wednesday, February 19th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $72.33.

Insiders Place Their Bets

In related news, CFO Kevin Feeley sold 3,749 shares of the stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $96.71, for a total transaction of $362,565.79. Following the completion of the sale, the chief financial officer now directly owns 8,492 shares of the company’s stock, valued at approximately $821,261.32. This represents a 30.63 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Katherine Stueland sold 46,551 shares of the firm’s stock in a transaction on Wednesday, March 26th. The stock was sold at an average price of $95.62, for a total transaction of $4,451,206.62. Following the sale, the chief executive officer now owns 48,314 shares in the company, valued at approximately $4,619,784.68. The trade was a 49.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 163,596 shares of company stock valued at $15,490,752. Company insiders own 27.30% of the company’s stock.

GeneDx Trading Down 0.1 %

WGS opened at $80.02 on Friday. GeneDx Holdings Corp. has a 1-year low of $8.63 and a 1-year high of $115.60. The firm has a 50-day moving average price of $88.11 and a two-hundred day moving average price of $75.56. The stock has a market capitalization of $2.25 billion, a PE ratio of -40.83 and a beta of 1.91. The company has a current ratio of 2.40, a quick ratio of 2.27 and a debt-to-equity ratio of 0.25.

GeneDx (NASDAQ:WGS) last issued its quarterly earnings results on Tuesday, February 18th. The company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.66. GeneDx had a positive return on equity of 3.33% and a negative net margin of 17.12%. The business had revenue of $95.64 million for the quarter, compared to analyst estimates of $82.24 million. As a group, equities analysts anticipate that GeneDx Holdings Corp. will post 0.97 earnings per share for the current fiscal year.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.